Carbamazepine Treatment in Patients Discontinuing Long-term Benzodiazepine Therapy: Effects on Withdrawal Severity and Outcome
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Forty patients with a history of difficulty discontinuing long-term, daily benzodiazepine therapy were randomly assigned, under double-blind conditions, to treatment with carbamazepine (200 to 800 mg/d) or placebo. A gradual taper (25% per week reduction) off benzodiazepine therapy was then attempted. Five weeks after taper, significantly more patients who had received carbamazepine than placebo remained benzodiazepine free, this despite the fact that no statistically significant differences in withdrawal severity could be demonstrated. Patients receiving carbamazepine reported a larger reduction in withdrawal severity than patients receiving placebo, but only at a trend level, and only on the daily patient-rated withdrawal checklist. Eleven patients (28%) required antidepressant therapy for depression or panic when assessed at 12-weeks follow-up. The results of this pilot investigation suggest that carbamazepine might have promise as an adjunctive drug therapy for the benzodiazepine withdrawal syndrome, particularly in patients receiving benzodiazepines in daily dosages of 20 mg/d or greater of diazepam equivalents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A few small studies have suggested the anticonvulsant carbamazepine might have limited effectiveness as an adjunct during the BZD tapering process to reduce anxiety and withdrawal symptoms.77,110–112”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [111]
In the citing paper
“A randomized clinical trial of 40 long-term benzodiazepine users tapering to discontinuation experienced symptoms of panic, anxiety, and depression to the point that 28% required antidepressant therapy at 12 weeks after benzodiazepine discontinuation”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [49]
In the citing paper
“However, by the end of the 12-week follow-up, this difference was no longer significant.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [90]
In the citing paper
“After 5 weeks of withdrawal, a higher proportion of individuals in the carbamazepine group remained BZD-free compared to the placebo group (95% versus 62%).”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [90]
In the citing paper
“Additionally, 28% of the participants required the introduction of antidepressants to manage symptoms of depression and anxiety during the follow-up. 90”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [90]
Citations
Cites
Rickels, K. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290060008 · Cited by 384
Self-citationLong-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Self-citationCLONIDINE IN BENZODIAZEPINE WITHDRAWAL
KESHAVAN, M. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92810-7 · Cited by 302
Benzodiazepine withdrawal symptoms and propranolol
TYRER, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92861-0 · Cited by 297
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191
Self-citationDouble-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.5.617 · Cited by 180
Willow, M., & Catterall, W. A. (1982) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15168-7 · Cited by 174
Specific and potent interactions of carbamazepine with brain adenosine receptors
Marangos, P. J., Post, R. M., Patel, J. B., Zander, K., Parma, A. M., & Weiss, S. R. B. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90135-8 · Cited by 138
Björkqvist, S. ‐., Isohanni, M., Mäkelä, R., & Malinen, L. (1976) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1976.tb00081.x · Cited by 119
Time‐course of interaction between carbamazepine and clonazepam in normal man
Lai, A. A., Levy, R. H., & Cutler, R. E. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978243316 · Cited by 107
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Treatment of Social Phobia With Gabapentin: A Placebo-Controlled Study
Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., Greist, J. H., & Sutherland, S. M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00010 · Cited by 395
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“There is some evidence to support carbamazepine in attenuating the withdrawal symptoms from benzodiazepines (Di Costanzo and Rovea, 1992; Garcia-Borreguero et al., 1991; Schweizer et al., 1991) (IIb).”
BackgroundWithdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
Metadata
- Authors
- Schweizer, E.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Schweizer, Edward
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1991-05-01
- Volume
- 48
- Issue
- 5
- Pages
- 448
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2151756295
- Cited by
- 138
- References
- 28
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 7 · 2019: 3 · 2018: 9 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 4
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-08957)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- carbamazepine, benzodiazepine withdrawal syndrome, benzodiazepine tapering, benzodiazepine discontinuation, adjunctive drug therapy, withdrawal severity, depression, panic disorder
- MeSH terms
- Benzodiazepines, Carbamazepine, Depressive Disorder, Diazepam, Double-Blind Method, Female, Humans, Male, Middle Aged, Pilot Projects, Placebos, Severity of Illness Index, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carbamazepine Treatment in Patients Discontinuing Long-term Benzodiazepine Therapy: Effects on Withdrawal Severity and Outcome. https://app.cochat.ai/papers/10.1001/archpsyc.1991.01810290060012
- The paper
- Schweizer, E. (1991). Carbamazepine Treatment in Patients Discontinuing Long-term Benzodiazepine Therapy: Effects on Withdrawal Severity and Outcome. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1991.01810290060012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.